GVV858

· Novartis Pharmaceuticals

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GVV858, covering 2026-02-23 to 2026-02-23. Get the full timeline:

Most recent: Clinical Trial Update: Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors [Phase 1, Phase 2]

See pricing